OTLK FY2025 EPS Lowered by Brookline Capital Management

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Analysts at Brookline Capital Management decreased their FY2025 earnings estimates for shares of Outlook Therapeutics in a research note issued on Wednesday, November 27th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($1.80) per share for the year, down from their previous forecast of ($1.64). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q4 2025 earnings at ($0.36) EPS, FY2026 earnings at $0.61 EPS and FY2027 earnings at $1.18 EPS.

Several other equities research analysts have also commented on the stock. BTIG Research lowered their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Friday, November 29th. Finally, Ascendiant Capital Markets dropped their price objective on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.34.

Outlook Therapeutics Trading Down 11.3 %

NASDAQ:OTLK opened at $1.80 on Monday. Outlook Therapeutics has a twelve month low of $0.87 and a twelve month high of $12.85. The company has a market cap of $42.59 million, a PE ratio of -0.17 and a beta of 0.46. The company’s 50 day moving average is $5.14 and its two-hundred day moving average is $6.62.

Institutional Trading of Outlook Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OTLK. Barclays PLC boosted its position in Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after buying an additional 18,249 shares during the period. Geode Capital Management LLC boosted its holdings in Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after purchasing an additional 112,812 shares during the period. XTX Topco Ltd acquired a new position in Outlook Therapeutics during the 3rd quarter worth $199,000. State Street Corp increased its holdings in Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after purchasing an additional 21,201 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock worth $275,000 after purchasing an additional 18,287 shares during the period. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Insider Buying and Selling

In other news, CFO Lawrence A. Kenyon purchased 5,000 shares of Outlook Therapeutics stock in a transaction dated Thursday, September 26th. The shares were purchased at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now owns 5,946 shares in the company, valued at $33,832.74. This represents a 528.54 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.40% of the stock is currently owned by company insiders.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.